20-18510875-C-T
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PP3PP5_Very_Strong
The NM_006363.6(SEC23B):c.40C>T(p.Arg14Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000124 in 1,613,968 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.00018 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00012 ( 0 hom. )
Consequence
SEC23B
NM_006363.6 missense
NM_006363.6 missense
Scores
8
8
3
Clinical Significance
Conservation
PhyloP100: 2.06
Genes affected
SEC23B (HGNC:10702): (SEC23 homolog B, COPII coat complex component) The protein encoded by this gene is a member of the SEC23 subfamily of the SEC23/SEC24 family, which is involved in vesicle trafficking. The encoded protein has similarity to yeast Sec23p component of COPII. COPII is the coat protein complex responsible for vesicle budding from the ER. The function of this gene product has been implicated in cargo selection and concentration. Multiple alternatively spliced transcript variants have been identified in this gene. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.805
PP5
Variant 20-18510875-C-T is Pathogenic according to our data. Variant chr20-18510875-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 1223.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SEC23B | NM_006363.6 | c.40C>T | p.Arg14Trp | missense_variant | 2/20 | ENST00000650089.1 | NP_006354.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SEC23B | ENST00000650089.1 | c.40C>T | p.Arg14Trp | missense_variant | 2/20 | NM_006363.6 | ENSP00000497473 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000178 AC: 27AN: 152088Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
27
AN:
152088
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000235 AC: 59AN: 251450Hom.: 0 AF XY: 0.000228 AC XY: 31AN XY: 135900
GnomAD3 exomes
AF:
AC:
59
AN:
251450
Hom.:
AF XY:
AC XY:
31
AN XY:
135900
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000118 AC: 173AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.000124 AC XY: 90AN XY: 727242
GnomAD4 exome
AF:
AC:
173
AN:
1461880
Hom.:
Cov.:
32
AF XY:
AC XY:
90
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000178 AC: 27AN: 152088Hom.: 0 Cov.: 33 AF XY: 0.000148 AC XY: 11AN XY: 74274
GnomAD4 genome
AF:
AC:
27
AN:
152088
Hom.:
Cov.:
33
AF XY:
AC XY:
11
AN XY:
74274
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
20
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:15
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 26, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 20, 2022 | One of the most common recurrent variants in the SEC23B gene and is considered a founder mutation in Italy, Morocco, and Israel (Russo et al., 2014); Published functional studies demonstrate a damaging effect: in vitro studies indicate the variant is unstable with less than 5% of the protein detectable compared to wild type (Schwarz et al., 2009); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21850656, 23935019, 19621418, 29846281, 20015893, 22208203, 33159567, 19561605, 25044164, 34426522, 31589614, 32641076) - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 21, 2022 | The SEC23B c.40C>T; p.Arg14Trp variant (rs121918222) has been reported in the literature as a founder mutation associated with congenital dyserythropoietic anemia type II (CDA II) in the Italian population (Russo 2011). In CDA II patients, the p.Arg14Trp variant was always detected along with an additional SEC23B pathogenic variant as a compound heterozygote (Aydin Koker 2018, Bianchi 2009, Iolascon 2010, Mansour-Hendili 2020, Mendez 2021, Moreno-Carralero 2018, Punzo 2011, Schwarz 2009). This SEC23B variant is reported as pathogenic in ClinVar (Variation ID: 1223). This variant is found in the general population with an overall allele frequency of 0.02% (67/282848 alleles) in the Genome Aggregation Database. The arginine at codon 14 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.75). In addition, in vitro functional analyses demonstrate that Arg14Trp-mutated SEC23B is extremely unstable with less than 5% of residual protein activity (Schwarz 2009). Based on available information, this SEC23B variant is considered to be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | SEC23B: PS3:Very Strong, PS4, PP1 - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 30, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 16, 2020 | PS3, PS4_moderate, PM3, PP1, PP5 - |
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The SEC23B p.R14W variant was identified in 36 of 178 proband chromosomes (frequency: 0.202; 1 homozygote, 3 heterozygotes, and 31 compound heterozygotes) from individuals or families with Congenital Dyserythropoietic Anemia type II (CDAII) (Punzo_2011_PMID:22208203; Russo_2011_PMID:21850656; Iolascon_2010_PMID:20015893; Bianchi_2009_PMID:19621418). A case report of an 18 year-old boy with chronic mild congenital anemia of unknown origin, chronic jaundice, and splenomegaly caused by non-autoimmune hemolytic anemia since 18 months of age was found to have two causative mutations in the SEC23B gene: the p.R14W variant and a novel frameshift deletion p.V164Wfs*3; the patient’s non-consanguineous parents with no history of anemia were heterozygous for either mutation (Koker_2018_PMID:29846281). The variant was identified in dbSNP (ID: rs121918222) and ClinVar (classified as pathogenic by Invitae, GeneDx and EGL Genetic Diagnostics for congenital dyserythropoietic anemia, type II). The variant was identified in control databases in 67 of 282848 chromosomes at a frequency of 0.0002369 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Latino in 21 of 35440 chromosomes (freq: 0.000593), Other in 4 of 7224 chromosomes (freq: 0.000554), European (non-Finnish) in 32 of 129154 chromosomes (freq: 0.000248), Ashkenazi Jewish in 2 of 10368 chromosomes (freq: 0.000193), East Asian in 3 of 19954 chromosomes (freq: 0.00015), South Asian in 3 of 30616 chromosomes (freq: 0.000098), African in 1 of 24972 chromosomes (freq: 0.00004), and European (Finnish) in 1 of 25120 chromosomes (freq: 0.00004). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Arg14 residue is conserved in mammals but not in more distantly related organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. Functional studies demonstrated that the p.R14W variant resulted in <5% of detectable protein compared to wildtype, however the p.R14W variant was coimmunoprecipitated by SEC24D simlarly to wildtype (Schwarz_2009_PMID:19561605). In addition, Satchwell et al. conducted in vitro studies to track the appearance of the CDAII phenotype during erythroblast differentiation in 5 unrelated patients, 3 of whom were compound heterozygotes for the p.R14W variant; patient erythroblasts displayed the characteristic CDAII phenotype including multinuclearity, erythrocyte membrane protein hypoglycosylation, and residual endoplasmic reticulum (Satchwell_2013_PMID:23935019). In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Congenital dyserythropoietic anemia, type II Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust | Mar 23, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 19, 2020 | Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with congenital dyserythropoietic anemia type II (MIM#224100). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to tryptophan. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (67 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (1 heterozygote, 0 homozygotes) (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in a compound heterozygous state with another pathogenic variant in multiple individuals (ClinVar, PMID: 19621418, 19561605, 25044164). (SP) 1205 - This variant has been shown to be maternally inherited (VCGS #20G001494). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2009 | - - |
Congenital dyserythropoietic anemia, type II;C4225179:Cowden syndrome 7 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 14 of the SEC23B protein (p.Arg14Trp). This variant is present in population databases (rs121918222, gnomAD 0.06%). This missense change has been observed in individual(s) with congenital dyserythropoietic anemia type II (PMID: 19561605, 19621418, 20015893, 21850656). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1223). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SEC23B protein function. Experimental studies have shown that this missense change affects SEC23B function (PMID: 19561605). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 29, 2022 | - - |
SEC23B-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 05, 2024 | The SEC23B c.40C>T variant is predicted to result in the amino acid substitution p.Arg14Trp. This variant has been reported to be causative for autosomal recessive congenital dyserythropoietic anemia (CDA) type II in the homozygous or compound heterozygous states (Bianchi et al. 2009. PubMed ID: 19621418; Schwarz et al. 2009. PubMed ID: 19561605; Iolascon et al. 2010. PubMed ID: 20015893; Russo et al. 2011. PubMed ID: 21850656). This variant is reported in 0.059% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
T;T;.;T;T;.;.;.;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;.;D;D;.;D;D;D;.;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;M;.;.;M;.;.;.;M;M
MutationTaster
Benign
A;A;A;A
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;.;D;D;.;.;.;.;D
REVEL
Pathogenic
Sift
Benign
T;T;.;D;T;.;.;.;.;T
Sift4G
Uncertain
D;D;.;D;D;.;.;.;.;D
Polyphen
D;D;.;.;D;.;.;.;D;D
Vest4
MVP
MPC
0.60
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at